Health and Healthcare
Amarin Shares Fall Despite Regulatory OK
Published:
Last Updated:
Usually, shares of drug makers soar following the announcement that the Foood and Drug Administration approved a drug.
Amarin Corp. (NASDAQ: AMRN) announced approval by the FDA for Vascepta to patients very high triglycerides. Yet, shares of the company are down 9.89% to $13.80 on trading volume of 14 million shares. The 52-week high is $15.96.
A part of the problem is that the stock was rising, albeit slowly, throughout the week based on anticipation for the announcement. While the FDA approval was expected, it hasn’t yet received approval for New Chemical Entity status to make sure there isn’t a generic competitor.
Investors are also looking for the company to be sold. Companies that could be strong candidates include AstraZeneca PLC (LSE: AZN), Pfizer, Inc. (NYSE: PFE) and Abbott Laboratories (NYSE: ABT), according to a Bloomberg article on Friday.
Samuel Weigley
The Easy Way To Retire Early
You can retire early from the lottery, luck, or loving family member who leaves you a fortune.
But for the rest of us, there are dividends. While everyone chases big name dividend kings, they’re missing the real royalty: dividend legends.
It’s a rare class of overlooked income machines that you could buy and hold – forever.
Click here now to see two that could help you retire early, without any luck required.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
